444289-22-9

Basic information

• Product Name: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide
• Synonyms: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide
• CAS NO: 444289-22-9
• Molecular Weight: 363.373
• Mol File: 444289-22-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide(444289-22-9)
• EPA Substance Registry System: N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)benzamide(444289-22-9)

Safety Data

• Hazardous Substances Data: 444289-22-9(Hazardous Substances Data)

Upstream product

• 827026-45-9 3-(4-nitro-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 98475-07-1 2-bromomethyl-3-nitro-benzoic acid methyl ester 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 2353-44-8 (+/-)-α-aminoglutarimide 
• 13726-85-7 Boc-Gln-OH 
• 65-85-0 benzoic acid 
• 98-88-4 benzoyl chloride 
• 879126-98-4 Lenalidomide 

Relevant articles and documents

Design, synthesis and biological evaluation of Lenalidomide derivatives as tumor angiogenesis inhibitor

Lenalidomide is a type of immunomodulatory agent with anti-tumor activity by mainly expressed in the anti-angiogenesis. In order to enhance the pharmacological activity of Lenalidomide, a series of Lenalidomide derivatives were designed as tumor angiogenesis inhibitors. The potential anti-angiogenesis targets of Lenalidomide derivatives were virtual screened on Auto-Dock 4.0 by using reverse docking method. The six target proteins, such as vascular endothelial growth factor receptor, epidermal growth factor receptor, fibroblast growth factor receptor, BCR-ABL tyrosine kinase, p38 mitogen activated protein kinase and metal protein kinase, were chosen as the targets. The Lenalidomide derivatives were synthesized by alkylated, acylated or sulfonylated Lenalidomide and verified by the 1H NMR, 13C NMR and LC–MS. Their anti-cancer activities were detected by using CCK-8 in the esophageal carcinoma cell line EC9706. The results indicate that the inhibitory activities of Lenalidomide derivatives were higher than that of Lenalidomide.